Cagrilintide is a long-acting dual amylin and calcitonin receptor agonist developed for obesity and related metabolic disorders. As an amylin analog, it works in the brain to reduce appetite, slow gastric emptying, and lower glucagon levels. Its activity is mediated through amylin receptors (AMY1R, AMY3R), which are formed by calcitonin receptors paired with receptor-modifying proteins.

In a phase II trial, Cagrilintide produced dose-dependent weight loss ranging from 6% to nearly 11% over 26 weeks, compared to about 3% with placebo. When combined with semaglutide (the investigational therapy “CagriSema”), results showed additive and superior weight reduction. This dual mechanism complements GLP-1 receptor agonists, positioning Cagrilintide as a potential partner in combination therapy for obesity and diabetes.